CYBB and Parkinson disease: We recently reported that pharmacological inhibition or genetic deletion of gp91phox, the catalytic subunit of NOX2 abrogates NF-κB activation and gene expression levels of microglial M1 markers29,43, which is associated with reduction of dopaminergic neurodegeneration in experimental PD models29,44.